Danyelza（naxitamab-gqgk）

On November 25th, 2020, Y-mAbs Therapeutics Company (Y-mAbs for short) announced that the US Food and Drug Administration (FDA) had accelerated the approval of its Danyelza(naxitamab-gqgk) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of relapsed/refractory high-risk neuromothers who showed partial remission, slight remission or disease stability.

[Recommended dosage and administration method of Danyelza(naxitamab-gqgk)]
Recommended dose
1. The recommended dosage of Danyelza on the 1st, 3rd and 5th day of each treatment cycle is 3mg/kg/ day (the maximum is 150mg/ day), which is given by intravenous infusion after dilution and combined with GM-CSF administered subcutaneously. The treatment cycle is repeated every four weeks until the condition is completely relieved or partially relieved, and then five cycles are repeated every four weeks, and the subsequent cycles can be repeated every eight weeks. If the disease worsens or has unacceptable toxicity, stop using Danyelza and GM-CSF.
2. In the process of infusion, pre-infusion drugs and supportive treatment are given as appropriate.

[Contraindications to Danyelza(naxitamab-gqgk)]
Danyelza is contraindicated in patients with a history of severe allergic reaction to naxitamab-gqgk.

[Adverse reaction of Danyelza(naxitamab-gqgk)]
1.Danyelza may cause serious side effects, such as hypertension: Hypertension is very common in people receiving Danyelza, and blood pressure should be monitored during Danyelza infusion, at least every day from the first day to the eighth day of each Danyelza treatment cycle. If you have any signs or symptoms of hypertension, please tell your doctor immediately, including: headache, epilepsy, nausea or vomiting, chest pain, dizziness, vision change, shortness of breath, feeling rapid heartbeat (palpitation), nose bleeding.
2. The most common side effects of 2.Danyelza include: increased heart rate, vomiting, cough, nausea, decreased counts of white blood cells, red blood cells and platelets, diarrhea, decreased appetite, fatigue, rash, decreased levels of potassium, sodium and phosphate in blood, urticaria, fever, headache, reaction at injection site, systemic or local body swelling, anxiety, irritability, increased blood test of liver function, decreased blood sugar level and blood calcium level.
3. The above are not all the adverse reactions of Danyelza. If there are other discomforts, please contact a doctor immediately.

Note: If there is any new packaging for drugs, the new packaging shall prevail. The above information comes from the Internet or translated by student volunteers in medical colleges and universities (if there are any mistakes or omissions, please help me to correct them). It is for internal discussion of medical staff only, without any basis for medication. Please consult the attending physician for specific medication guidelines.